392 related articles for article (PubMed ID: 11207278)
1. CD95 ligand-expressing tumors are rejected in anti-tumor TCR transgenic perforin knockout mice.
Behrens CK; Igney FH; Arnold B; Möller P; Krammer PH
J Immunol; 2001 Mar; 166(5):3240-7. PubMed ID: 11207278
[TBL] [Abstract][Full Text] [Related]
2. Tumor immunity in perforin-deficient mice: a role for CD95 (Fas/APO-1).
Rosen D; Li JH; Keidar S; Markon I; Orda R; Berke G
J Immunol; 2000 Mar; 164(6):3229-35. PubMed ID: 10706715
[TBL] [Abstract][Full Text] [Related]
3. Perforin- and Fas-dependent mechanisms of natural killer cell-mediated rejection of incompatible bone marrow cell grafts.
Taylor MA; Ward B; Schatzle JD; Bennett M
Eur J Immunol; 2002 Mar; 32(3):793-9. PubMed ID: 11870623
[TBL] [Abstract][Full Text] [Related]
4. A central role for death receptor-mediated apoptosis in the rejection of tumors by NK cells.
Screpanti V; Wallin RP; Ljunggren HG; Grandien A
J Immunol; 2001 Aug; 167(4):2068-73. PubMed ID: 11489989
[TBL] [Abstract][Full Text] [Related]
5. The influence of CD95L expression on tumor rejection in mice.
Igney FH; Behrens CK; Krammer PH
Eur J Immunol; 2003 Oct; 33(10):2811-21. PubMed ID: 14515265
[TBL] [Abstract][Full Text] [Related]
6. Tumor regression after adoptive transfer of effector T cells is independent of perforin or Fas ligand (APO-1L/CD95L).
Winter H; Hu HM; Urba WJ; Fox BA
J Immunol; 1999 Oct; 163(8):4462-72. PubMed ID: 10510388
[TBL] [Abstract][Full Text] [Related]
7. IFN-gamma promotes Fas ligand- and perforin-mediated liver cell destruction by cytotoxic CD8 T cells.
Roth E; Pircher H
J Immunol; 2004 Feb; 172(3):1588-94. PubMed ID: 14734739
[TBL] [Abstract][Full Text] [Related]
8. IL-4 diminishes perforin-mediated and increases Fas ligand-mediated cytotoxicity In vivo.
Aung S; Graham BS
J Immunol; 2000 Apr; 164(7):3487-93. PubMed ID: 10725701
[TBL] [Abstract][Full Text] [Related]
9. Tumor-specific CTL kill murine renal cancer cells using both perforin and Fas ligand-mediated lysis in vitro, but cause tumor regression in vivo in the absence of perforin.
Seki N; Brooks AD; Carter CR; Back TC; Parsoneault EM; Smyth MJ; Wiltrout RH; Sayers TJ
J Immunol; 2002 Apr; 168(7):3484-92. PubMed ID: 11907109
[TBL] [Abstract][Full Text] [Related]
10. Clonal deletion of major histocompatibility complex class I-restricted CD4+CD8+ thymocytes in vitro is independent of the CD95 (APO-1/Fas) ligand.
Müller KP; Mariani SM; Matiba B; Kyewski B; Krammer PH
Eur J Immunol; 1995 Oct; 25(10):2996-9. PubMed ID: 7589104
[TBL] [Abstract][Full Text] [Related]
11. Decreased tumor surveillance in perforin-deficient mice.
van den Broek ME; Kägi D; Ossendorp F; Toes R; Vamvakas S; Lutz WK; Melief CJ; Zinkernagel RM; Hengartner H
J Exp Med; 1996 Nov; 184(5):1781-90. PubMed ID: 8920866
[TBL] [Abstract][Full Text] [Related]
12. Functional role of CD95 ligand in concanavalin A-induced intestinal intraepithelial lymphocyte cytotoxicity.
Ghoreschi K; Muders M; Enders GA
Immunology; 1998 Dec; 95(4):566-71. PubMed ID: 9893046
[TBL] [Abstract][Full Text] [Related]
13. CD95L mediates tumor counterattack in vitro but induces neutrophil-independent tumor rejection in vivo.
Igney FH; Behrens CK; Krammer PH
Int J Cancer; 2005 Jan; 113(1):78-87. PubMed ID: 15386427
[TBL] [Abstract][Full Text] [Related]
14. Induction of antitumor immunity with Fas/APO-1 ligand (CD95L)-transfected neuroblastoma neuro-2a cells.
Shimizu M; Fontana A; Takeda Y; Yagita H; Yoshimoto T; Matsuzawa A
J Immunol; 1999 Jun; 162(12):7350-7. PubMed ID: 10358186
[TBL] [Abstract][Full Text] [Related]
15. Transgenic expression of CD95 ligand on thyroid follicular cells confers immune privilege upon thyroid allografts.
Tourneur L; Malassagne B; Batteux F; Fabre M; Mistou S; Lallemand E; Lores P; Chiocchia G
J Immunol; 2001 Aug; 167(3):1338-46. PubMed ID: 11466351
[TBL] [Abstract][Full Text] [Related]
16. The regulation of CD95 (Fas) ligand expression in primary T cells: induction of promoter activation in CD95LP-Luc transgenic mice.
Norian LA; Latinis KM; Eliason SL; Lyson K; Yang C; Ratliff T; Koretzky GA
J Immunol; 2000 May; 164(9):4471-80. PubMed ID: 10779747
[TBL] [Abstract][Full Text] [Related]
17. Functional defects of NK cells treated with chloroquine mimic the lytic defects observed in perforin-deficient mice.
Austin Taylor M; Bennett M; Kumar V; Schatzle JD
J Immunol; 2000 Nov; 165(9):5048-53. PubMed ID: 11046034
[TBL] [Abstract][Full Text] [Related]
18. Acute rejection of allografted CTL-susceptible leukemia cells from perforin/Fas ligand double-deficient mice.
Nomi H; Tashiro-Yamaji J; Yamamoto Y; Miura-Takeda S; Miyoshi-Higashino M; Takahashi T; Azuma H; Ueda H; Katsuoka Y; Kubota T; Yoshida R
J Immunol; 2007 Aug; 179(4):2180-6. PubMed ID: 17675477
[TBL] [Abstract][Full Text] [Related]
19. Transplantation of CD95 ligand-expressing grafts: influence of transplantation site and difficulty in protecting allo- and xenografts.
Seino K; Kayagaki N; Tsukada N; Fukao K; Yagita H; Okumura K
Transplantation; 1997 Oct; 64(7):1050-4. PubMed ID: 9381528
[TBL] [Abstract][Full Text] [Related]
20. In vivo rejection of tumor cells dependent on CD8 cells that kill independently of perforin and FasL.
Lee SH; Bar-Haim E; Machlenkin A; Goldberger O; Volovitz I; Vadai E; Tzehoval E; Eisenbach L
Cancer Gene Ther; 2004 Mar; 11(3):237-48. PubMed ID: 14739939
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
